Seeking Alpha
 

Johnson & Johnson (JNJ)

- NYSE
  • Jul. 30, 2012, 10:56 AM
    J&J (JNJ +0.2%) unit Synthes is being sued for wrongful death and negligence by the family of a patient who died in 2003 after she was injected with a bone cement as part of an illegal trial. The suit adds to two other cases brought in the scandal, which saw four execs go to prison.
    | Comment!
  • Jul. 25, 2012, 11:46 AM
    Eli Lilly (LLY +2.7%) CEO John Lechleiter says to use caution when extrapolating the failed clinical trials of Pfizer (PFE -0.5%) and Johnson & Johnson's (JNJ +0.2%) Alzheimer's candidate, bapineuzumab, to solanezumab, the one that [LLY has in its pipeline. "We've got to be very careful before we draw conclusions," Lechleiter says. There are differences between the drugs, how they bond for example, that could allow for different outcomes. The company expects to report clinical data for solanezumab later in Q3.  (Video)
    | Comment!
  • Jul. 23, 2012, 5:33 PM
    Pfizer (PFE) says an experimental Alzheimer's treatment it's working on with Johnson & Johnson (JNJ) unit Janssen Pharmaceuticals did not meet clinical endpoints in a late-stage study. In the study, patients with mild-to-moderate Alzheimer's disease given an intravenous form of the drug bapineuzumab didn't fare any better in cognitive and functional performance than those given a placebo. Elan (ELN), which holds a 49.9% equity interest in Janssen Alzheimer Immunotherapy, is taking a big hit after hours: PFE -1.3%, JNJ -0.2%, ELN -16.8%.
    | 1 Comment
  • Jul. 17, 2012, 11:09 AM
    SA author Stephen Simpson says J&J (JNJ -0.7%) had a decent Q2, with an encouraging underlying performance in the company's drug and orthopedics ops. Simpson's main concern is the devices and diagnostics arms, the latter seeming to be slipping "further and further behind." Still, J&J "looks like a worthwhile name for conservative investors looking for healthcare exposure."
    | Comment!
  • Jul. 17, 2012, 8:12 AM
    More on J&J's (JNJ) Q2: Net profit falls to $1.41B from $2.78B; Q2 2012 includes special items of $2.2B, comprising a write-down related to J&J's Crucell (CRXL) vaccine ops, provision for litigation, costs connected to Synthes acquisition. Cuts 2012 EPS outlook to $5.00-$5.07 from up to $5.17. Consensus is $5.14. Shares -1.4%. (PR)
    | Comment!
  • Jul. 17, 2012, 7:55 AM
    Johnson & Johnson (JNJ): Q2 EPS of $1.30 beats by $0.01. Revenue of $16.5B (-0.7% Y/Y) misses by $200M. Shares -1.2% premarket. (PR)
    | Comment!
  • Jul. 17, 2012, 12:05 AM
    Notable earnings before Tuesday's open: AMTD, CMA, EDU, FRX, GS, HST, JNJ, KO, KSU,MAT, MMR, MOS, MTB, OMC, SCHW, STT
    | Comment!
  • Jul. 16, 2012, 5:30 PM
    Notable earnings before Tuesday's open: AMTD, CMA, EDU, FRX, GS, HIST, JNJ, KO, KSU,MAT, MMR, MOS, MTB, OMC, SCHW, STT
    | Comment!
  • Jul. 16, 2012, 10:59 AM
    Johnson & Johnson (JNJ): Declares $0.61/share quarterly dividend, in line with previous. Forward yield 3.6%. For shareholders of record Aug 28; Payable Sep 11; ex-div date Aug 24. (PR)
    | Comment!
  • Jul. 12, 2012, 6:06 AM
    J&J (JNJ) could face a bill of almost $4.8B to cover revision surgery for its Pinnacle metal-on-metal hip system, estimates attorney Brian Devine, who is handling cases in which the device has failed. That would add to the $3B J&J has shelled out following the recall of its ASR all-metal artificial hips two years ago.
    | Comment!
  • Jul. 9, 2012, 8:40 AM
    The FDA grants priority review to Bayer's (BAYRY.PK) and J&J's (JNJ) blood-clotting treatment Xarelto for use against deep vein thrombosis and pulmonary embolism, and the prevention of venous thromboembolism in people who have already had it. However, Bayer withdraws its request to use Xarelto to lower the risk of blood clots in heart-stent patients.
    | Comment!
  • Jul. 8, 2012, 7:41 AM
    Seven DJIA components have hit all-time highs this year (vs. 8 in 2011), with JNJ and AXP seemingly next in line. Many of the blue chips boast strong balance sheets, consistent cash flows, and yields matching or beating Treasurys - adaptive managements are thrown in for free. What's not to like?
    | 21 Comments
  • Jul. 2, 2012, 12:16 PM
    J&J (JNJ +0.4%) is seeking accelerated FDA approval for bedaquiline, the first new type of drug to treat tuberculosis in over four decades, and the first for specifically fighting the increasingly common strain of the disease that is resistant to multiple drugs. J&J filing is supported by data from a Phase II trial. (PR)
    | Comment!
  • Jun. 28, 2012, 10:53 AM
    Pharmaceutical stocks are down following the Supreme Court healthcare opinion, although not dramatically: AZN -0.4%, GSK -1.6%, SNY -0.8%, PFE -0.8%, ABT -0.8%, MRK -0.7%, LLY -1%, WPI -0.9%, NVS -0.7%, JNJ -0.4%. iShares Dow Jones US Healthcare ETF (IYH) -0.95%, the Health Care SPDR (XLV) is -1.3%.
    | 2 Comments
  • Jun. 25, 2012, 2:58 PM
    The FDA will convene an advisory panel meeting this week to discuss metal-on-metal hip implants made by Johnson & Johnson (JNJ -0.2%) and Zimmer Holding (ZMH -1.8%), which have been the subject of thousands of patient lawsuits. The metal devices have been linked to almost 16,800 adverse events in the U.S. between 2000 and 2011, according regulators, and need more consistent testing to help lower high failure rates that lead to risky replacement surgeries. (draft report)
    | Comment!
  • Jun. 22, 2012, 1:55 PM
    Johnson & Johnson (JNJ +0.4%) receives a favorable Barron's write-up. The paper talks up J&J's 3.7% dividend yield, low P/E, diverse product line, and new drug launches, along with its recently-closed acquisition of medical device maker Synthes. (earlier)
    | Comment!
Visit Seeking Alpha's
JNJ vs. ETF Alternatives
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale ofproducts in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.